The combination of PD-1 inhibitors and anti-angiogenic agents has increased the 1-year OS from a range of 36%-60% to 92% according to data from Checkmate-141 and BGB-A317-102, which used anti–PD-1 monotherapy in later treatment lines for R/M HNSCC and nasopharyngeal carcinoma (10, 32). This evidence concerns the gene PDCD1 and nasopharyngeal carcinoma.